June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Agreement between Compass Fundus Perimeter New Grid and 10-2 Testing Protocols for Detecting Central Visual Field Defects
Author Affiliations & Notes
  • Nevin W. El-Nimri
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Christopher Bowd
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Rafaella Penteado
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • James A Proudfoot
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Huiyuan Hou
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Patricia Isabel C. Manalastas
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Elham Ghahari
    Ophthalmology, University of California San Diego, La Jolla, California, United States
    Ophthalmology, University of Kentucky, Lexington, Kentucky, United States
  • Linda M Zangwill
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Sasan Moghimi
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Robert N Weinreb
    Ophthalmology, University of California San Diego, La Jolla, California, United States
  • Footnotes
    Commercial Relationships   Nevin El-Nimri, None; Christopher Bowd, None; Rafaella Penteado, None; James Proudfoot, None; Huiyuan Hou, None; Patricia Manalastas, None; Elham Ghahari, None; Linda Zangwill, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering GmbH (F), Merck (C), National Eye Institute (F), Optovue (R), Optovue Inc. (F), Topcon Medical Systems (R), Topcon Medical Systems Inc. (F); Sasan Moghimi, None; Robert Weinreb, Allergan (C), Bausch & Lomb (C), Carl Zeiss Meditec Inc. (F), Centervue (F), Eyenovia (C), Heidelberg Engineering (F), Konan (F), National Eye Institute (F), Nicox (C), Topcon (F)
  • Footnotes
    Support  EY11008, EY19869, EY14267, EY027510, EY026574, EY027945, EY029058, P30EY022589, and participant retention incentive grants in the form of glaucoma medication at no cost from Novartis/Alcon Laboratories Inc, Allergan, Akorn, and Pfizer Inc. Unrestricted grant from Research to Prevent Blindness, New York, New York.
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 3376. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nevin W. El-Nimri, Christopher Bowd, Rafaella Penteado, James A Proudfoot, Huiyuan Hou, Patricia Isabel C. Manalastas, Elham Ghahari, Linda M Zangwill, Sasan Moghimi, Robert N Weinreb; Agreement between Compass Fundus Perimeter New Grid and 10-2 Testing Protocols for Detecting Central Visual Field Defects. Invest. Ophthalmol. Vis. Sci. 2021;62(8):3376.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the agreement between Compass New Grid (NG) and Compass10-2 test protocols for detecting early glaucomatous defects in the central 10 degrees of the visual field (CVFD).

Methods : 123 eyes of 14 healthy individuals, 17 glaucoma suspects and 32 glaucoma patients performed NG and 10-2 automated perimetry measurements within one week and macular scans using Spectralis OCT within 12 months. For both test protocols total deviation (TD) or pattern deviation (PD) plot CVFDs were defined in either superior or inferior hemifields by three contiguous points with probabilities of <5%, <2%, <2% or <5%, <1%, <1%. Cohen’s Kappa (k) statistic was used to assess agreement between NG and 10-2 for identifying CVFDs. The Spectralis GMPE Hood Glaucoma Report (investigational software version) macula deviation analysis was used to identify macular defects as areas of thickness with p ≤ 0.05 covering three or more contiguous 10-2 test points in the superior and inferior hemiretina for calculating sensitivities and specificities of all test protocols.

Results : Low to moderate agreement was observed between NG and 10-2 protocols for detecting presence of superior CVFDs on TD (k=0.566) and PD (k=0.256) plots and for detecting inferior CVFDs on TD (0.487) and PD (0.272) plots. Specificity of NG and 10-2 TD plots for detecting superior CVFDs was 0.82 and 0.65, respectively. Specificity of NG and 10-2 TD plots for detecting inferior CVFDs was 0.92 and 0.84, respectively. Specificity of NG and 10-2 PD plots for detecting superior CVFDs was 0.81 and 0.36, respectively. Specificity of NG and 10-2 PD plots for detecting inferior CVFDs was 0.86 and 0.52, respectively. Sensitivity of NG and 10-2 plots ranged from 0.20 for NG PD plot inferior defects to 0.78 for 10-2 PD plot superior defects.

Conclusions : Because agreement between the detection of central visual fields defects using Compass New Grid and 10-2 is fair to moderate, the visual field test results may be complementary and are not interchangeable.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×